A Study to Evaluate the Pharmacokinetics of the Enteric-Coated Micronized Free Base Formulation of Darapladib [SB-480848] and Its Metabolites in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2012
At a glance
- Drugs Darapladib (Primary)
- Indications Asthma; Atherosclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 05 Aug 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2008 New trial record.